Cytotoxicity of Novel Redox Sensitive PEG2000-S-S-PTX Micelles against Drug-Resistant Ovarian and Breast Cancer Cells
- 12 March 2020
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 37 (3) , 1-8
Abstract
Purpose Since the last decade, it is established that nonspecific delivery of chemotherapeutics fails to effectively treat cancer due to systemic cytotoxicity, poor biodistribution at tumor site and most importantly the development of drug resistance (MDR). Stimuli-sensitive drug delivery systems gained significant attention in recent years for effective tumor therapy and reversal of MDR. The aim of this study was developing a redox sensitive micellar prodrug system, by taking the advantage of the significant difference in GSH levels between extracellular and intracellular environments, but more importantly in healthy and tumor tissues. Methods Redox sensitive PEG2000-S-S-PTX micelles were developed for intracellular paclitaxel delivery and characterized in vitro. In vitro release studies were carried out and followed by cytotoxicity studies in chemo-resistant ovarian and breast cancer cells in various reducing environments for different time periods to confirm their potential. Results PEG2000-S-S-PTX, was synthesized and characterized as a redox sensitive micellar prodrug system. The reduction sensitivity and in vitro PTX release properties were confirmed in reducing environments comparatively with physiological conditions. Cytotoxicity studies suggested that ovarian (SK-OV-3) cells could be better candidates for treatment with redox-sensitive drug delivery systems than breast (MCF-7) cancer cells. Conclusions The results of this study highlights the importance of personalized therapy since no fits-for-all system can be developed for different cancer with significantly different metabolic activities. Schematic representation of self-assembly of reduction-sensitive PEG2000-S-S-PTX micelles and GSH dependent release of PTXKeywords
Funding Information
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
This publication has 34 references indexed in Scilit:
- Paclitaxel Formulations: Challenges and Novel Delivery OptionsCurrent Drug Delivery, 2014
- Barriers to drug delivery in solid tumorsTissue Barriers, 2014
- Preparation and in vitro properties of redox-responsive polymeric nanoparticles for paclitaxel deliveryColloids and Surfaces B: Biointerfaces, 2011
- The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effectAdvanced Drug Delivery Reviews, 2011
- Tumor delivery of macromolecular drugs based on the EPR effectAdvanced Drug Delivery Reviews, 2011
- Enhanced Permeability and Retention (EPR) Effect for Anticancer Nanomedicine Drug Targeting2010
- Nanoparticle and targeted systems for cancer therapyAdvanced Drug Delivery Reviews, 2004
- Nanoparticles in cancer therapy and diagnosisAdvanced Drug Delivery Reviews, 2002
- Paclitaxel and its formulationsInternational Journal of Pharmaceutics, 2002
- Drug targetingEuropean Journal of Pharmaceutical Sciences, 2000